{
    "2020-08-24": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Novartis' Immunotherapy Fails in Late-Stage Skin Cancer Study",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Immunotherapy",
                        "Fails",
                        "Late-Stage",
                        "Skin Cancer"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis Skin Cancer Drug Combination Involving Spartalizumab Fails Clinical Trial",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Skin Cancer",
                        "Drug Combination",
                        "Spartalizumab",
                        "Fails",
                        "Clinical Trial"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis CEO says COVID-19 makes valuing takeover targets tougher",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "COVID-19",
                        "Valuing",
                        "Takeover",
                        "Tougher"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "corporate strategy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Stocks - Europe Seen Higher Amid Virus Treatment Optimism",
                "features": {
                    "keywords": [
                        "Stocks",
                        "Europe",
                        "Higher",
                        "Virus Treatment",
                        "Optimism"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "economy",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}